Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.51 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 6/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21091782 | 0.90 | CYP2C9 (0.41) | CYP2C9P2RX3DGAT2WDR5PTGS2 | |
| SCHEMBL16504277 | 0.90 | CYP2C9 (0.41) | CYP2C9P2RX3DGAT2WDR5PTGS2 | |
| SCHEMBL13092755 | 0.87 | CYP2C9 (0.49) | CYP2C9P2RX3DGAT2WDR5ROCK2 | |
| SCHEMBL16504276 | 0.85 | CYP2C9 (0.48) | CYP2C9P2RX3DGAT2WDR5ROCK2 | |
| SCHEMBL13095464 | 0.85 | P2RX3 (0.66) | CYP2C9P2RX3DGAT2ROCK2MAPK1 | |
| SCHEMBL2263089 | 0.84 | CYP2C9 (0.52) | CYP2C9P2RX3DGAT2WDR5ROCK2 | |
| SCHEMBL2264658 | 0.80 | CYP2C9 (0.55) | CYP2C9P2RX3DGAT2WDR5ROCK2 | |
| SCHEMBL13095479 | 0.79 | P2RX3 (0.79) | CYP2C9P2RX3DGAT2WDR5ROCK2 | |
| SCHEMBL2261464 | 0.78 | CYP2C9 (0.52) | CYP2C9P2RX3DGAT2WDR5ROCK2 | |
| SCHEMBL12388301 | 0.77 | CYP2C9 (0.47) | CYP2C9P2RX3DGAT2WDR5ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | claimed |
| EP-2215049-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2019-06-12 | — | — | EP | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | CYP2C9 4126/4885P2RX3 1/4885DGAT2 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.